Pfizer and Celltrion Healthcare Report Real-World Study Results of CT-P13 (biosimilar, infliximab) for Inflammatory Bowel Disease
Shots:
- The real-world study evaluates CT-P13 vs Remicade in 115 patients aged 44yrs. wit IBD incl. CD & UC at 24 sites in US & Canada for 12mos. For CD, 30.8% were biologic-naïve & 6.7% switched from reference infliximab & had a clinical response to treatment
- The results demonstrated positive clinical & PROs. In UC & CD patients, 35.4% & 72.7% were in remission at baseline & 87.1% & 77.1% @12mos. In biologic-naïve patients with UC, the remission rate increased from 5.6% at baseline to 90.9% @12mos., and the avg. pMAYO decreased from 5.67 to 1.09 while remission rate & HBI scores did not change from baseline to 12mos. for CD. The results were published in Advances in Therapy
- Patients switched from the reference infliximab, remission rates at baseline & 12mos. (75.4% & 83.0%), 9.6% reported IBD-related hospitalization
Ref: The Center For Biosimilars | Image: Pfizer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
